Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025
Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Fineline Cube Dec 29, 2025
Company Medical Device

Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device

Fineline Cube Jul 7, 2023

Singapore-based Genesis MedTech has announced that it has received market approval in China for its...

Company Drug

Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval

Fineline Cube Jul 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study

Fineline Cube Jul 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development

Fineline Cube Jul 7, 2023

China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...

Company Deals

ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion

Fineline Cube Jul 7, 2023

China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...

Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Company Deals

Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007

Fineline Cube Jul 7, 2023

Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...

Company Deals

Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy

Fineline Cube Jul 6, 2023

Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...

Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study

Fineline Cube Jul 6, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Deals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy

Fineline Cube Jul 6, 2023

Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...

Company Deals

Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies

Fineline Cube Jul 6, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...

Policy / Regulatory

NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety

Fineline Cube Jul 6, 2023

The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...

Company Policy / Regulatory

China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities

Fineline Cube Jul 6, 2023

This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...

Company Legal / IP

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Fineline Cube Jul 6, 2023

Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...

Company

Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production

Fineline Cube Jul 6, 2023

US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...

Posts pagination

1 … 441 442 443 … 601

Recent updates

  • Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
  • J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
  • Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership
  • NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue
  • NMPA Issues Internet Pharma Info Rules Requiring Record-Filing Display
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.